================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 7, 2003
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
Delaware 1-1136 22-079-0350
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrant's telephone number, including area code: (212) 546-4000
================================================================================
ITEM 5. OTHER EVENTS.
On January 7, 2003, the Registrant announced in a press release that it
has agreed to settle substantially all of the antitrust litigation surrounding
two of its drugs, BuSpar(R) and TAXOL(R). Incorporated by reference is the press
release issued by the Registrant on January 7, 2003, attached as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements of Business to be Acquired: Not Applicable.
(b) Pro Forma Financial Information: Not Applicable.
(c) Exhibits
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press Release dated January 7, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Bristol-Myers Squibb Company,
By: /s/ SANDRA LEUNG
--------------------------------
Name: Sandra Leung
Title: Secretary
Date: January 31, 2003
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press Release dated January 7, 2003